TransCode Therapeutics (NASDAQ: RNAZ) has announced the initiation of a Phase 2a clinical trial evaluating its lead therapeutic candidate, TTX-MC138, in patients with colorectal cancer who have minimal residual disease. The trial will enroll up to 45 patients who remain circulating tumor DNA-positive after receiving curative-intent therapy, despite showing no radiographic evidence of disease. This patient population is at high risk for recurrence, and the study aims to assess the biological and clinical activity of TTX-MC138 in reducing that risk.
The trial is being conducted in collaboration with Quantum Leap Healthcare Collaborative through its PRE-I-SPY clinical trial platform. This platform is designed to efficiently evaluate novel therapies in earlier-stage disease settings. The study will focus on patients with microRNA-10b overexpression, a biomarker associated with metastasis. TTX-MC138 is designed to target this microRNA, potentially preventing the spread of cancer cells.
According to the company, TTX-MC138 has shown promise in preclinical models for its ability to inhibit metastasis. The Phase 2a trial represents a significant step forward in bringing this therapy to patients. For more details on the trial, visit the full press release at https://ibn.fm/wuRri.
TransCode Therapeutics is a clinical-stage company focused on developing RNA-based therapeutics for cancer. Its lead candidate, TTX-MC138, targets metastatic tumors that overexpress microRNA-10b, a well-documented biomarker of metastasis. The company also has a portfolio of other first-in-class therapeutic candidates designed to mobilize the immune system against cancer cells.
The initiation of this trial is a critical milestone for TransCode and for patients with colorectal cancer who face a high risk of recurrence despite initial treatment. If successful, TTX-MC138 could offer a new option for preventing metastasis, which is the leading cause of cancer-related deaths.
For the latest news on TransCode Therapeutics, visit the company's newsroom at https://ibn.fm/RNAZ.
